Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherNot yet recruiting Location: Australia

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis. , protocol number ACTRN12606000053527

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis.

    • Age:

      No limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      >40% pred.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Australia - NSW, QLD, SA, VIC, WA

    Prevention of Bronchiectasis in Infants with Cystic Fibrosis , protocol number NCT01270074

    The general aim of this project is to conduct a randomised, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.

    • Age:

      Maximum 6 months

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Australia - NSW, QLD, SA

    Insulin Deficiency, Early Action , protocol number NCT01100892

    Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. Te CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.

    • Age:

      5 - 19 Years

    • Mutation(s):

      CFID1 or CFID2

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis? , protocol number ACTRN12605000728639

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis?

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    Evaluation of CF patient perception of symptom improvement following inhaled antibiotic treatment. , protocol number ACTRN12605000602628

    Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).

    • Age:

      6 years - no stated upper limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of a targetted exercise program versus current exercise practice on function, activity and participation of young people with cystic fibrosis: a randomised, controlled trial , protocol number ACTRN12607000612415

    Exercise is a vital component of the physiotherapy management for young people with cystic fibrosis (CF). The overall aim of this research is to strengthen knowledge about best practice exercise programs for this population. This study compares effects of two exercise programs (the current exercise practice versus a novel targeted exercise program). Ultimately, it is expected that with improved exercise programs, young people with CF may have improved body structure and function, and activity and participation levels, leading to enhanced quality of life.

    • Age:

      18-70 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40% predicted or above

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Mucociliary ClearanceRecruiting Location: Melbourne, Sydney, Newcastle and Brisbane, Australia

    A randomised, double blind, study of inhaled alginate oligosaccharide (OligoG) compared to placebo in patients with Cystic Fibrosis , protocol number ORDCF205

    This clinical trial is to investigate whether inhaled OligoG dry powder for inhalation (DPI) is effective in the treatment of Cystic Fibrosis, and to further evaluate the safety and tolerability of OligoG DPI. Participants will be treated for 12 weeks with either OligoG, or placebo, while continuing to use any medications that they are already using. Following the results of the 12 week treatment, patients will be offered open label treatment with OligoG for 48 weeks, while continuing to use any medications they are currently using. Only suitable for participants taking continuous or cyclic inhaled antibiotics, and no simultaneous unstable illness. Direct your enquiry to National Office.

    • Age:

      18 years and Older

    • Mutation(s):

      No mutation requirement - Only suitable for participants not taking CFTR modulators

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      7

    • Length of Participation:

      12 weeks (followed option of access to Oligog for 1 year, with 5 study visits)

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Monash Health - Melbourne

    Cystic Fibrosis Related Diabetes (CFRD) Model of care: Optimising Patient Centred Healthcare Delivery in the Inpatient and Outpatient Setting , protocol number RES-18-0000-183 Monash Health Ref RES-18-0000-183 Monash Health Ref

    Cystic Fibrosis Related Diabetes Clinical Care Do you have cystic fibrosis related diabetes (CFRD)? Do you feel that clinical services managing CFRD could be improved upon? We want to hear your thoughts on how clinical care for CFRD can be optimised. The purpose of this research is to determine the requirements of adult patients with CFRD. We wish to assess barriers and enablers to provision of optimal care of adults with CFRD with a view to ultimately improving clinical outcomes for all people with CFRD. If you would like to participate, please follow the link to an anonymous survey that should take about 15 minutes to complete. Click here to complete CFRD survey This research has been initiated by the researchers at Monash Medical Centre in Melbourne, Victoria. This project has been approved by Monash Health Human Research Ethics Committee.

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      1

    • Length of Participation:

      approx. 30 mins

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Australian Sites: Adelaide, Brisbane, Melbourne, Newcastle, Sydney Westmead, Sydney Randwick, Perth

    Saline Hypertonic in pre-schoolers + CT (SHIP-CT) , protocol number NCT02950883 & ACTRN12615001067561p SHIP002 (SHIPCT)

    The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks reduces structural lung disease as assessed by computed tomography (CT) in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 6) with cystic fibrosis.

    • Age:

      3-5 years

    • Mutation(s):

      A documented genotype with two disease-causing mutations in the CFTR gene

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      6

    • Length of Participation:

      54 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA & Australia

    Phase 3 study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides. , protocol number NCT02139306 PTC124-GD-021-CF

    This study is taking place at multiple care centers across the U.S. It looked at the effectiveness and safety of the oral drug ataluren in people with CF who have a nonsense mutation of cystic fibrosis. This study used a placebo control.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      56 weeks

    Contact us about this clinical Trial >
  • Displaying results 31-40 (of 193)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|